What question did this study set out to answer?

This study evaluates the impact of baseline CD4 count on outcomes for patients with HIV-associated lymphoma.

December 8, 2025Blood

Baseline CD4 count is associated with early mortality in HIV-associated lymphoma: A retrospective cohort study

View Full Paper

Ask AI

Bookmark

This study evaluates the impact of baseline CD4 count on outcomes for patients with HIV-associated lymphoma.
Retrospective review of 49 PLWH diagnosed with lymphoma from 2014 to 2021.
Assessments included CD4 count, ART status, insurance type, and lymphoma subtype.
Statistical analyses involved Kaplan-Meier survival estimates and Cox proportional hazards models.
Median overall survival was 2.5 years, and median progression-free survival was 1.6 years.
Patients with CD4 count >100 had 1.28 years longer average overall survival than those with CD4 count ≤100.
Forty-five percent of patients achieved a complete response to treatment.

No takes yet. Share an insight, caveat, or question.

Retrospective cohort reveals lower progression-free survival in PLWH with CD4 count ≤100, suggesting immune status affects diagnosis outcomes.

Law et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort reveals lower progression-free survival in PLWH with CD4 count ≤100, suggesting immune status affects diagnosis outcomes.